The localization of EGFR at the TJ barrier, where its activity needs to be tightly controlled to drive and, likely, maintain barrier function, provides a novel perspective on why cancer patients treated with EGFR inhibitors develop skin rashes of unknown origin50. The gene discussed is EGFR; the disease is cancer.